Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.50 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4602895 | 1.00 | DNM1 (0.50) | DNM1PLA2G1BPLA2G2ALMNAALDH1A1 | |
| SCHEMBL4603260 | 1.00 | DNM1 (0.50) | DNM1PLA2G1BPLA2G2ALMNAALDH1A1 | |
| SCHEMBL11230062 | 1.00 | DNM1 (0.50) | DNM1PLA2G1BPLA2G2ALMNAALDH1A1 | |
| SCHEMBL4603220 | 1.00 | DNM1 (0.50) | DNM1PLA2G1BPLA2G2ALMNAALDH1A1 | |
| SCHEMBL3244458 | 0.92 | DNM1 (0.56) | DNM1PLA2G1BPLA2G2ALMNAALDH1A1 | |
| SCHEMBL3244619 | 0.92 | DNM1 (0.56) | DNM1PLA2G1BPLA2G2ALMNAALDH1A1 | |
| SCHEMBL4602550 | 0.89 | DNM1 (0.41) | DNM1ALDH1A1 | |
| SCHEMBL10719786 | 0.87 | ALDH1A1 (0.50) | DNM1ALDH1A1TSHR | |
| SCHEMBL4556813 | 0.84 | TSHR (0.47) | DNM1LMNATSHRSMPD1OPRM1 | |
| SCHEMBL211947 | 0.84 | TSHR (0.47) | DNM1LMNATSHRSMPD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227865-A1 | COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-09-18 | — | — | US | claimed |
| US-7425577-B2 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2008-09-16 | — | — | US | claimed |
| EP-1660062-B1 | USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-07-09 | — | — | EP | claimed |
| US-20060199869-A1 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2006-09-07 | — | — | US | claimed |
| US-20080227865-A1 | COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-7425577-B2 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2008-09-16 | — | — | US | disclosed |
| EP-1660062-B1 | USE OF COLIPASE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | FORSKARPATENT I SYD AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20060199869-A1 | Lipase-colipase inhibitor | FORSKARPATENT 1 SYD AB (SE) | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199869-A1 | Lipase-colipase inhibitor | PNLIP, LPL, LIPC | DNM1 3975/4885PLA2G1B 151/4885PLA2G2A 338/4885 |
| US-20080227865-A1 | COLIPSE-LIPASE INHIBITORS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION IN ORDER TO PREVENT OBESITY | PNLIP, LIPE, LPL | DNM1 4358/4885PLA2G1B 118/4885PLA2G2A 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.